University of Cambridge and Elan Pharmaceutical team up against AD
Dublin/Cmbridge (UK) – The University of Cambridge and Irish drugmaker Elan Pharmaceutical have joined forces in the battle against Alzheimer’s Disease. Together, the two will create a new research centre dedicated to investigating degenerative brain disorders. Elan will be investing US-$10 million in the initial five years of the collaboration, with an option to extend it by a further five years. The goal of the Cambridge-Elan Centre for Research Innovation and Drug Discovery is to discover novel compounds capable of altering the behaviour of proteins associated with neurodegenerative disorders. „Based on this understanding, in conjunction with scientists at Elan, these compounds will be translated into new treatments to prevent these diseases“, said Christopher Dobson, the John Humphrey Plummer Professor of Chemical and Structural Biology at the University of Cambridge and St. John’s College. The research will focus on the protein beta amyloid, which in the brain of Alzheimer patients aggregates and ultimately forms amyloid plaques. „Protein folding, misfolding and turnover are central to neurological disease and will be the basis for further scientific and therapeutic advancement“, commented Ted Yednock, PhD, executive vice president and head of discovery and translation for Elan. His colleague, Dale Schenk, executive vice president and chief scientific officer added that the deal would be in line with Elan’s portfolio of programs in neuroscience and supports the process of discovery which would result in a new line of therapeutics.